Dr Ranjitha Rao

Associate Professor

Department of Pathology

CURRENT ACADEMIC ROLE & RESPONSIBILITIES

    Associate Professor

SUBJECTS CURRENTLY TEACHING

Subject Semester / Year
Pathology III, IV, V semester MBBS

ACADEMIC QUALIFICATIONS

Degree Specialisation Institute Year of passing
MD Pathology Karnataka Institute of Medical Sciences, Hubli 2014
MBBS Karnataka Institute of Medical Sciences, Hubli 2010

Experience

Institution / Organisation Designation Role Tenure
Kasturba Medical College, Mangalore Assistant Professor Nov 2014 – till date

AREAS OF INTEREST, EXPERTISE AND RESEARCH

Area of Interest

Histopathology with special interest in gynecologic pathology,breast pathology,cytopathology and transfusion medicine

Area of Expertise

Histopathology, cytopathology

Area of Research

Breast and gynecologic pathology

Professional Affiliations & Contributions

KCIAPM

1.    Rao R, Deviprasad D, Jaipuria B, Saha  D ,Manisha N, Rao K S (2018) Mantle Cell Lymphoma of the Palatine Tonsil: A Rare Case Report. Iran J Otorhinolaryngol. 2018 ;30(100):297-300

2.    Rao R, Giriyan SS, Rangappa P K. Clinicopathological profile of papillary carcinoma of thyroid: A 10-year experience in a tertiary care institute in North Karnataka, India. Indian J Cancer 2017;54:514-8

3.    Venkataramana CG,  Pai RR, Rao R, Nirupama M,Lobo FD,  Sahoo KK.Clinicopathological study of medullary carcinoma of thyroid: A single institute experience.Thyroid Res Pract 2018;15:38-41.

4.    Govindarajan S, Adiga DS,Lobo F D, Rao  R, Prasad K, Venkataramana CG Advanced Stage Lung Cancer: Persisting Challenges in the Era of Molecular Targeted Therapy-Our Experience.JCDR 2018;12 (5):14-17.

5.    Venkataramana CG,Kini H, Saha D, Rai S, Adiga D S, Rao R,Philipose C S.Histomorphologic Spectrum in Hyaline Vascular Variant of Castleman Disease. JCDR 2017;11 (8): EC01-EC04.

1. A study of p63 expression in papillary lesions of the breast to evaluate its utility as a marker to distinguish benign from malignant lesions. 2. A study of Oct-4/POU5F1, a stem cell transcription factor expression in breast cancer and its impact on the prognosis . 3. Advanced Stage Lung Cancer: Persisting Challenges in the Era of Molecular Targeted Therapy-Our Experience.